Last reviewed · How we verify
TRIAMTERENE
At a glance
| Generic name | TRIAMTERENE |
|---|---|
| Drug class | Thiazide Diuretic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
Boxed warnings
- WARNINGS: Hyperkalemia: Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-conserving diuretic combinations, including triamterene and hydrochlorothiazide. Hyperkalemia is more likely to occur in patients with renal impairment, diabetes (even without evidence of renal impairment), or elderly or severely ill patients. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients first receiving triamterene and hydrochlorothiazide, when dosages are changed or with any illness that may influence renal function.
Common side effects
- Nausea and vomiting
- Weakness
- Fatigue
- Dizziness
- Headache
- Dry mouth
- Diarrhea
- Hyperkalemia
- Hypokalemia
- Rash
Serious adverse events
- Anaphylaxis
- Acute renal failure
- Irreversible renal failure
- Acute interstitial nephritis
- Azotemia
- Renal stones
- Elevated BUN and creatinine
- Thrombocytopenia
- Megaloblastic anemia
- Jaundice and/or liver enzyme abnormalities
Key clinical trials
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
- Treatment of Meniere's Disease With Migraine Medications (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- A Crossover Pilot Study of the Effect of Amiloride on Proteinuria (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease (NA)
- Diuretics, Hypertension, and Arrhythmias Clinical Trial (PHASE3)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIAMTERENE CI brief — competitive landscape report
- TRIAMTERENE updates RSS · CI watch RSS